Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07291973

Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures.

Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures. — Recruiting • Non-phase study •…

📅 10 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07291973
Sponsor
Endowave Ltd.
Start
2025-10-24
ClinicaliQ Trial Snapshot
  • Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures. — Recruiting • Non-phase study • Oncology • NCT07291973.
  • What is being tested: The Endowave FlexAblate™ Microwave Ablation System's effectiveness and safety profile for treating lung cancer nodules using microwave ablation technology as a minimally invasive intervention.
  • Patient eligibility overview: The trial enrolls patients with lung cancer nodules who are candidates for ablation procedures; specific eligibility criteria including tumour size, location, and patient performance status would be detailed in the full protocol.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will also learn about the safety of the ablation system. Participants in this clinical trial will be patients aged over 18 years who have been previously diagnosed with cancer in the lung (primary or secondary malignant tumours) and deemed unsuitable for surgery or are declining surgery or, patients suitable for microwave ablation procedure based on clinical assessment. Those who meet all of the eligibility criteria at a…

Eligibility Snapshot
  • : * Adult ≥ 18 years of age who has provided signed informed consent. * Subject is able and willing to comply with the planned clinical investigation follow-up schedule * Pathological confirmed malignant nodule in the lung either primary or metastatic disease. * Target nodule is ≤ 20mm in maximum diameter. * There is ≥ 5mm of nodule-free lung parenchyma between target nodule and pleura or fissure. * Subject is a candidate for an elective lung ablation procedure as determined by institutional multi-disciplinary board or equivalent. * Subject or the lesion is not suitable for surgery or patient refuses surgery.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Oncology · 07 May 2026
Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of…
View guideline →
Guideline
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
Oncology · 06 May 2026
Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for…
View guideline →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →
Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Guideline
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
Oncology · 28 Apr 2026
Ripretinib is recommended as an option for adults with advanced gastrointestinal stromal tumours who have received 3 or more prior kinase inhibitors…
View guideline →
Guideline
2023 ESMO Clinical Practice Guidelines: Metastatic Non-Small Cell Lung Cancer
Oncology · 30 Mar 2026
Covers diagnostic workup and molecular profiling for metastatic non-small cell lung cancer (NSCLC) • Provides treatment algorithms based on biomarker status (EGFR,…
View guideline →